See more : Peak Bancorp Inc. (IDFB) Income Statement Analysis – Financial Results
Complete financial analysis of Intercept Pharmaceuticals, Inc. (ICPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intercept Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Electreon Wireless Ltd (ELWS.TA) Income Statement Analysis – Financial Results
- GobiMin Inc. (GMNFF) Income Statement Analysis – Financial Results
- Arakawa Chemical Industries, Ltd. (4968.T) Income Statement Analysis – Financial Results
- Arvind Fashions Limited (ARVINDFASN.NS) Income Statement Analysis – Financial Results
- BlackRock MuniHoldings California Quality Fund, Inc. (MUC) Income Statement Analysis – Financial Results
Intercept Pharmaceuticals, Inc. (ICPT)
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 285.71M | 363.47M | 312.69M | 252.00M | 179.80M | 130.96M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
Cost of Revenue | 984.00K | 3.10M | 5.32M | 4.21M | 2.52M | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 284.73M | 360.37M | 307.37M | 247.79M | 177.29M | 129.59M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
Gross Profit Ratio | 99.66% | 99.15% | 98.30% | 98.33% | 98.60% | 98.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
Research & Development | 176.64M | 185.27M | 191.49M | 242.80M | 207.30M | 191.50M | 153.89M | 128.19M | 80.31M | 27.94M | 16.18M | 11.43M | 12.71M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 255.47M | 0.00 | 0.00 | 103.75M | 34.60M | 13.13M | 4.85M | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -161.00 | 331.87K | 0.00 | 0.00 |
SG&A | 176.30M | 230.86M | 332.49M | 317.42M | 255.47M | 273.70M | 273.60M | 103.75M | 34.60M | 13.13M | 5.18M | 4.21M | 3.64M |
Other Expenses | 6.52M | 2.16M | 4.41M | 8.89M | 6.77M | 4.52M | 3.90M | 2.73M | 776.00K | 100.38K | -104.00K | 0.00 | 104.55K |
Operating Expenses | 352.94M | 416.13M | 523.98M | 560.22M | 462.78M | 465.20M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
Cost & Expenses | 353.93M | 419.23M | 529.30M | 564.43M | 465.29M | 466.57M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
Interest Income | 15.51M | 47.77M | 39.80M | 33.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.45K | 0.00 |
Interest Expense | 21.39M | 54.42M | 48.05M | 41.14M | 30.52M | 29.27M | 14.20M | 0.00 | 0.00 | 0.00 | 0.00 | 13.48K | 0.00 |
Depreciation & Amortization | 6.52M | 2.16M | 4.41M | 8.89M | 4.58M | 4.60M | 3.83M | 1.69M | 442.80K | 105.68K | 201.32K | 410.60K | 479.50K |
EBITDA | -61.70M | -53.60M | -212.20M | -303.54M | -278.72M | -331.10M | -398.63M | -226.43M | 57.66M | -10.90M | 5.71M | -14.46M | -16.06M |
EBITDA Ratio | -21.59% | -14.75% | -67.86% | -120.45% | -155.01% | -252.83% | -1,597.67% | -8,139.07% | 3,310.10% | -672.47% | 233.52% | -801.31% | 0.00% |
Operating Income | -68.22M | -55.76M | -216.61M | -312.43M | -285.49M | -335.61M | -402.54M | -229.16M | -113.17M | -39.45M | -18.91M | -14.88M | -16.35M |
Operating Income Ratio | -23.88% | -15.34% | -69.27% | -123.98% | -158.78% | -256.28% | -1,613.31% | -8,237.10% | -6,496.56% | -2,432.85% | -773.25% | -824.06% | 0.00% |
Total Other Income/Expenses | -106.64M | -35.67M | -43.64M | -32.25M | -23.75M | -24.76M | -10.29M | 2.73M | -170.06M | -28.34M | -24.73M | 0.00 | 1.27M |
Income Before Tax | -174.86M | -91.43M | -274.88M | -344.68M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -13.83M | -15.09M |
Income Before Tax Ratio | -61.20% | -25.15% | -87.91% | -136.78% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -766.17% | 0.00% |
Income Tax Expense | -290.03M | 53.60M | 49.35M | 46.37M | 6.77M | 29.19M | 14.27M | 1.04M | 170.39M | 28.44M | 24.42M | -1.09M | -672.48K |
Net Income | 115.17M | -145.02M | -324.23M | -391.05M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -12.74M | -15.09M |
Net Income Ratio | 40.31% | -39.90% | -103.69% | -155.18% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -705.64% | 0.00% |
EPS | 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
EPS Diluted | 3.40 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
Weighted Avg Shares Out | 33.82M | 31.86M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
Weighted Avg Shares Out (Dil) | 33.84M | 31.89M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
US FDA declines full approval for Intercept's liver disease drug
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
FDA advisers vote against confirmatory data for Intercept's liver disease drug
FDA staff raises efficacy concerns over Intercept's liver disease drug
Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Source: https://incomestatements.info
Category: Stock Reports